Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial
Naomi E Hammond, Simon R Finfer, Qiang Li, Colman Taylor, Jeremy Cohen, Yaseen Arabi, Rinaldo Bellomo, Laurent Billot, Meg Harward, Christopher Joyce, Colin McArthur, John Myburgh, Anders Perner, Dorrilyn Rajbhandari, Andrew Rhodes, Kelly Thompson, Steve Webb, Balasubramanian Venkatesh
Intensive Care Medicine | SPRINGER | Published : 2020
PURPOSE: To investigate the impact of hydrocortisone treatment and illness severity on health-related quality of life (HRQoL) at 6 months in septic shock survivors from the ADRENAL trial. METHODS: Using the EuroQol questionnaire (EQ-5D-5L) at 6 months after randomization we assessed HRQoL in patient subgroups defined by hydrocortisone or placebo treatment, gender, illness severity (APACHE II < or ≥ 25), and severity of shock (baseline peak catecholamine doses < or ≥ 15 mcg/min). Additionally, in subgroups defined by post-randomisation variables; time to shock reversal (days), treatment with renal replacement therapy (RRT), and presence of bacteremia. RESULTS: At 6 months, there were 2521 sur..View full abstract
Awarded by National Health and Medical Research Council of Australia
Awarded by Health Research Council of New Zealand
This study was supported by project grants from the National Health and Medical Research Council of Australia (Grant Numbers: 1004108 and 1124926) and the Health Research Council of New Zealand (grant number: 12/306), by indirect funding from the National Institute of Health Research in the United Kingdom, and by Practitioner Fellowships from the National Health and Medical Research Council of Australia (to Drs. Venkatesh, Finfer, Bellomo, and Myburgh).